tbuckley/cabot-search huggingface dataset:
ROUTINE APPLICATION OF A LIPID-LOWERING TREATMENT ALGORITHM BEFORE DISCHARGE AFTER ACUTE MYOCARDIAL INFARCTION DESIGNED TO TARGET AN LDL-C &lt;55 MG/DL (1.4 MMOL/L)
Authors: Francois Schiele, Camille Buonvino, Jean Ferrières, Michel Farnier, Eric Bruckert, Michel Krempf, Romain Chopard
Journal: Journal of the American College of Cardiology (2020)
Neoadjuvant concurrent chemoradiation therapy followed by surgical resection in patients with non-small cell lung cancer invading chest wall.
Authors: Yoko Yamaguchi, Kiyotaka Yoh, Tomoyuki Hishida, Hironobu Ohmatsu, Koichi Goto, Seiji Niho, Shigeki Umemura, Genichiro Ishii, Tetsuo Akimoto, Kanji Nagai, Yuichiro Ohe
Journal: Journal of Clinical Oncology (2012)

e17554 Background: The treatment approach of patients with non-small-cell lung cancer (NSCLC) invading the chest wall (stage T3N0M0) is still controversial. The clinical outcome of NSCLC patients with chest wall invasion has remained poor. The purpose of this study was to determine the efficacy and safety of neoadjuvant concurrent chemoradiation therapy followed by surgical resection in NSCLC patients with chest wall invasion. Methods: We retrospectively reviewed medical records of 19 patients with NSCLC invading chest wall (T3N0M0 or T4N0M0), who underwent neoadjuvant concurrent chemoradiation therapy followed by surgical resection between April 2003 and October 2009. Neoadjuvant chemotherapy was administered intravenously at cisplatin 80 mg/m 2 on day 1 and vinorelbine 20 mg/m 2 on days 1 and 8, q4w, with a maximum of 2 cycles. Radiotherapy directed at the primary tumor invading chest wall was started in cycle 1, at the total dose of 45Gy in 25 fractions. Surgical resection of the tumor was performed 4 to 8 weeks after the completion of neoadjuvant therapy. Results: Patient characteristics included: median age 61 years (range 43-68); Male/Female=17/2; and stage T3N0M0/T4N0M0=18/1. Six patients (32%) had superior sulcus tumors. Neoadjuvant chemoradiation therapy was generally well tolerated. All patients underwent surgical resection, and complete resection was achieved in 18 patients (95%). There were 10 (53%) patients with pathologic complete response. There were no treatment-related deaths. The 3-year disease-free and overall survival rates for all patients were 58% and 81%, respectively, with a median follow-up of 37 months. The 3-year disease-free survival rate was 78% for patients with a pathologic complete response compared with 25% for those who did not achieve a pathologic complete response. Disease progression occurred mainly in distant sites. Conclusions: Neoadjuvant chemotherapy consists of cisplatin-vinorelbine and radiotherapy followed by surgical resection is effective and tolerable in patients with NSCLC invading chest wall (T3N0M0). This treatment approach produces high rates of pathologic complete response.
RHYTHM DISTURBANCES IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
Authors: Jae Hyung Cho, Derek Leong, Joseph Ebinger, Sung-Han Yoon, Catherine Bresee, Ashkan Ehdaie, Michael Shehata, Xunzhang Wang, Sumeet S. Chugh, Eduardo Marban, Eugenio Cingolani
Journal: Journal of the American College of Cardiology (2020)
COMPARISON OF ECHOCARDIOGRAPHIC OUTCOMES FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT WITH EDWARDS S3 23 MM VERSUS MEDTRONIC EVOLUT 26 MM VALVES
Authors: Michael E. Ring, Ruyun Jin, Rollie Parrish, Brydan Curtis, Mathew Forrester, Branden R. Reynolds, Sameer Gafoor
Journal: Journal of the American College of Cardiology (2020)
Traffic-related Air Pollution, Dust Mite Allergen, and Childhood Asthma in Puerto Ricans
Authors: Erica L. Stevens, Franziska Rosser, Yueh-Ying Han, Erick Forno, Edna Acosta-Pérez, Glorisa Canino, Juan C. Celedón
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Hemispheric asymmetry in the human brain and in Parkinson’s disease is linked to divergent epigenetic patterns in neurons
Authors: Peipei Li, Elizabeth Ensink, Sean Lang, Lee Marshall, Meghan Schilthuis, Jared Lamp, Irving Vega, Viviane Labrie
Journal: Genome biology (2020)

Abstract Background Hemispheric asymmetry in neuronal processes is a fundamental feature of the human brain and drives symptom lateralization in Parkinson’s disease (PD), but its molecular determinants are unknown. Here, we identify divergent epigenetic patterns involved in hemispheric asymmetry by profiling DNA methylation in isolated prefrontal cortex neurons from control and PD brain hemispheres. DNA methylation is fine-mapped at enhancers and promoters, genome-wide, by targeted bisulfite sequencing in two independent sample cohorts. Results We find that neurons of the human prefrontal cortex exhibit hemispheric differences in DNA methylation. Hemispheric asymmetry in neuronal DNA methylation patterns is largely mediated by differential CpH methylation, and chromatin conformation analysis finds that it targets thousands of genes. With aging, there is a loss of hemispheric asymmetry in neuronal epigenomes, such that hemispheres epigenetically converge in late life. In neurons of PD patients, hemispheric asymmetry in DNA methylation is greater than in controls and involves many PD risk genes. Epigenetic, transcriptomic, and proteomic differences between PD hemispheres correspond to the lateralization of PD symptoms, with abnormalities being most prevalent in the hemisphere matched to side of symptom predominance. Hemispheric asymmetry and symptom lateralization in PD is linked to genes affecting neurodevelopment, immune activation, and synaptic transmission. PD patients with a long disease course have greater hemispheric asymmetry in neuronal epigenomes than those with a short disease course. Conclusions Hemispheric differences in DNA methylation patterns are prevalent in neurons and may affect the progression and symptoms of PD.
A molecular network regulating the proinflammatory phenotype of human memory T lymphocytes
Authors: Stefan Emming, Niccolò Bianchi, Sara Polletti, Chiara Balestrieri, Cristina Leoni, Sara Montagner, Michele Chirichella, Nicolas Delaleu, Gioacchino Natoli, Silvia Monticelli
Journal: Nature Immunology (2020)
LONG-TERM (10-YEAR) COMPARATIVE OUTCOMES OF STENTING OR BYPASS SURGERY FOR LEFT MAIN CORONARY ARTERY DISEASE IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS
Authors: Duk-Woo Park, Kyusup Lee, Do-Yoon Kang, Hanbit Park, Sang-Cheol Cho, Jung-Min Ahn, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2020)
LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 LEVELS, ENDOTHELIAL DYSFUNCTION AND ARTERIAL STIFFNESS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASELIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 LEVELS, ENDOTHELIAL DYSFUNCTION AND ARTERIAL STIFFNESS IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE
Authors: Evangelos Oikonomou, Konstantinos Mourouzis, Gerasimos Siasos, Marina Zaromitidou, Vicky Tsigkou, Evanthia Bletsa, Vasiliki Chara Mystakidi, Athina Goliopoulou, Paraskevi Papanikolaou, Panagiota Stampouloglou, Manolis Vavuranakis, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2020)
Ethnic minority patients receive worse mental healthcare than white patients, review finds
Authors: Jacqui Thornton
Journal: BMJ (2020)

Doctors are more uncertain when it comes to diagnosing emotional problems and depression in ethnic minority patients, a new report has suggested.

Although the Race Equality Foundation found no evidence of direct racial discrimination in assessments, its review highlighted evidence indicating ethnic bias.1

The report found a wide range of inequalities linked to mental illness in black, Asian, and other ethnic minority communities. It called on commissioners to understand the persistent nature of these inequalities and recognise ways to tackle them. It added that better data collection and quality were needed to improve evidence based policies and interventions, which may lead to a greater focus on preventing mental illness.

The report, which focused on five specific areas of prevalence, access, assessment, treatment, and recovery, drew on the most recently published research from …
Complement-activated interferon-γ–primed human endothelium transpresents interleukin-15 to CD8+ T cells
Authors: Catherine B. Xie, Bo Jiang, Lingfeng Qin, George Tellides, Nancy C. Kirkiles-Smith, Dan Jane-wit, Jordan S. Pober
Journal: Journal of Clinical Investigation (2020)

Alloantibodies in presensitized transplant candidates deposit complement membrane attack complexes (MACs) on graft endothelial cells (ECs), increasing risk of CD8+ T cell-mediated acute rejection. We recently showed that human ECs endocytose MACs into Rab5+ endosomes, creating a signaling platform that stabilizes NF-κB-inducing kinase (NIK) protein. Endosomal NIK activates both noncanonical NF-κB signaling to synthesize pro-IL-1β and an NLRP3 inflammasome to process and secrete active IL-1β. IL-1β activates ECs, increasing recruitment and activation of alloreactive effector memory CD4+ T (Tem) cells. Here, we report that IFN-γ priming induced nuclear expression of IL-15/IL-15Rα complexes in cultured human ECs and that MAC-induced IL-1β stimulated translocation of IL-15/IL-15Rα complexes to the EC surface in a canonical NF-κB-dependent process in which IL-15/IL-15Rα transpresentation increased activation and maturation of alloreactive CD8+ Tem cells. Blocking NLRP3 inflammasome assembly, IL-1 receptor, or IL-15 on ECs inhibited the augmented CD8+ Tem cell responses, indicating that this pathway is not redundant. Adoptively transferred alloantibody and mouse complement deposition induced IL-15/IL-15Rα expression by human ECs lining human coronary artery grafts in immunodeficient mice, and enhanced intimal CD8+ T cell infiltration, which was markedly reduced by inflammasome inhibition, linking alloantibody to acute rejection. Inhibiting MAC signaling may similarly limit other complement-mediated pathologies.
THE ROLE OF SLEEPING PATTERNS IN CAROTID ATHEROSCLEROSIS: INSIGHTS FROM THE CORINTHIA STUDY
Authors: Evangelos Oikonomou, Sotirios Tsalamandris, Georgia Vogiatzi, Panagiotis Theofilis, Athina Goliopoulou, George Lazaros, Evagelia Christoforatou, Christos Chasikidis, Vasiliki Mistakidi, Maria Anastasiou, Nikolaos Galiatsatos, Margenti Papakonstantinou, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2020)
Gene network transitions in embryos depend upon interactions between a pioneer transcription factor and core histones
Authors: Makiko Iwafuchi, Isabel Cuesta, Greg Donahue, Naomi Takenaka, Anna B. Osipovich, Mark A. Magnuson, Heinrich Roder, Steven H. Seeholzer, Pilar Santisteban, Kenneth S. Zaret
Journal: Nature Genetics (2020)
Managing COVID-19 in Low- and Middle-Income Countries
Authors: Joost Hopman, Benedetta Allegranzi, Shaheen Mehtar
Journal: JAMA (2020)

Yan Bai, MD; Lingsheng Yao, MD; Tao Wei, MD; Fei Tian, MD; Dong-Yan Jin, PhD; Lijuan Chen, PhD; Meiyun Wang, MD, PhD
Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr)
Authors: J. Berlin, M. Neubauer, P. Swanson, W. G. Harker, H. Burris, J. R. Hecht, L. Navale
Journal: Journal of Clinical Oncology (2006)

3548 Background: Panitumumab is a fully human monoclonal antibody directed against EGFr. We investigated panitumumab antitumor activity in pts who failed prior therapy and had EGFr tumor expression levels ≥ 10%. Methods: In this multicenter, phase 2 study of 300 planned pts, pts had documentation of disease progression (PD) during or following adequate doses of fluoropyrimidine, irinotecan, and oxaliplatin (centrally confirmed refractory disease [CCRD]), 2–3 prior regimens, ECOG score 0–2, and EGFr staining (by IHC) in ≥ 10% of evaluable tumor cells. Pts received panitumumab at 6 mg/kg Q2W until PD. Tumor assessments (modified WHO, blinded central review) were taken periodically from wk 8–48 until PD. Study endpoints were objective response rate (ORR) at wk 16 (+ ≥ 4 wk confirmation; primary) and ORR throughout study, response duration, progression-free survival (PFS) time, survival time, and safety (secondary). Results: In this interim analysis (5/05), 91 enrolled pts received ≥ 1 dose of panitumumab (safety set); 39 had ≥ 20 wks before the cutoff and CCRD (efficacy set). The efficacy set consisted of 23M/16W, mean (SD) age of 58.6 (10.1) years, 82% white, 95% ECOG ≤ 1, 74% colon cancer and 26% rectal cancer; all had ≥ 2 prior regimens (equivalent characteristics for safety set). At wk 16, 3 (8%) had a partial response, 8 (21%) had stable disease, and 19 (49%) had PD as best OR (9 not done/unevaluable). At the time of this interim analysis, response durations were 12.4, 13.2, and 14.0 wks. In the safety set, 96% had at least 1 treatment-related adverse event (24% grade [gr] 3, 1% gr 4, 1% gr 5). Integument and eye toxicities were: 96% skin, 30% nail, 8% eye, 5% hair, and 7% chelitis. 25 (27%) had diarrhea (3 gr 3); 11 (12%) had hypomagnesemia (3 gr 3/4). One pt had a gr 3 hypersensitivity reaction considered related to panitumumab, received medication, and the event resolved; this pt continued treatment with premedication; no further reactions occurred. In 66 pts with both a baseline and postdose sample, no human anti-human antibodies to panitumumab were detected.Additional data will be presented. Conclusions: Panitumumab has antitumor activity and is well tolerated in pts with EGFr tumor expression levels ≥ 10% who failed standard chemotherapy. [Table: see text]
CARDIOVASCULAR OUTCOMES FOLLOWING BORTEZOMIB REINITIATION AFTER CONGESTIVE HEART FAILURE DIAGNOSIS IN MULTIPLE MYELOMA
Authors: Valentina Jaramillo Restrepo, Vishal S. Shah, Tania Jain, Jeremy T. Larsen, Hemalatha Narayanasamy, Reza Arsanjani, Brian W. Hardaway, Farouk Mookadam, Carolyn Larsen
Journal: Journal of the American College of Cardiology (2020)
ACUTE LEFT ATRIAL STRAIN CHANGES BEFORE AND AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Richard Ro, Stamatios Lerakis, Karthik Seetharam, Prathyusha Bande, Parasuram Krishnamoorthy, Nagendra Boopathy Senguttuvan, Gilbert Tang, Gila Perk, Samin K. Sharma, Annapoorna Subhash Kini
Journal: Journal of the American College of Cardiology (2020)
Breast cancer in the elderly: An area for improvement.
Authors: Sakshi Jasra, Vipra Sharma, Alice J. Cohen, Nicole Jabel
Journal: Journal of Clinical Oncology (2012)

e16565 Background: Treatment (TX) of breast cancer (BC) in elderly (E) patients (pt) can be problematic due to the increased co-morbidities (CM), multiple medications, and cognitive dysfunction related to age. Due to this many E pt are less likely to have standardized treatment (TX). This study was undertaken to assess if pt over the age of 70 diagnosed with BC received TX based on NCCN guidelines and what CM led to selection of therapies. Methods: A retrospective review at a tertiary care medical center identified 108 pt over the age of 70 with BC from 2001-2011. Clinical data was obtained regarding race, age, stage (ST) at diagnosis, TX, CM, estrogen receptor (ER), progesterone receptor (PR), and HER2neu receptor (H2N) status. Results: Of the 108 pts, 22% were Caucasians, 66% were African-American, 3% Asian, 6% Hispanic, and 2% other. The age range was 70 to 96 years, mean of 75. Staging was as follows: 23% DCIS, 24% ST I, 28% ST II, 9% ST III, and 7% ST IV. 66% were ER positive (+), 60% PR+, and 87% H2N negative. H2N status was not available on 9% of the pts. In 92% of the pt surgical intervention (SI), either lumpectomy (L) with radiation therapy (RT), or mastectomy (M) was done (see table below). 8% of pt either refused SI or were lost to follow-up. ER/PR+ pt hormone therapy (HT) was started in 95% of pt. 3% of ER/PR+ pt refused HT. In stage II and III 60% of pt had adjuvant chemotherapy (CT), only 5% refused CT. In ST IV 30% had HT alone, 50% with CT and HT, and 25% with RT to chest wall for local recurrence. Only 23% of H2N positive pt received Herceptin. 52% of the CT used in stage II and III was cyclophosphamide, methotrexate, fluorouracil (CMF). CM in the CMF pts were as follows 90% cardiovascular disease (CAD), 53% arthritis (AR), 13% history malignancy, and 13% pulmonary disease. In the pt who refused SI, and/or CT the most common CM were 70% CAD, 50% AR, and 25% dementia. Conclusions: The majority of the E BC pt in this cohort had significant CM that made TX challenging. Some pt were not offered appropriate CT (i.e., trastuzumab) due to CM. Age impacts BC TX, but should not hinder the pt receiving optimal tx. Further studies with women over the age of 70 with BC is required to determine the most appropriate TX in this subset of pts. [Table: see text]
ASSOCIATION BETWEEN TOTAL CORONARY BURDEN AND HIGH-SENSITIVITY CARDIAC TROPONIN-T IN PSORIASIS
Authors: Karthik Vedantam, Wunan Zhou, Rajus Chopra, Amit Dey, Jenis Argueta-Amaya, Justin Rodante, Martin Playford, Alan Remaley, Marcus Y. Chen, Nehal Mehta, National Heart
Journal: Journal of the American College of Cardiology (2020)
EARLY CATHETER-BASED STENT INTERVENTIONS DO NOT IMPROVE PULMONARY ARTERY GROWTH OR CARDIAC FUNCTION COMPARED TO DELAYED INTERVENTIONS IN A SWINE PULMONARY ARTERY STENOSIS MODEL
Authors: Luke J. Lamers, Ryan Pewowaruk, Kevin Pettit, Joshua Hermsen, John Carter Ralphe, Alejandro Roldan
Journal: Journal of the American College of Cardiology (2020)
Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity.
Authors: Andrew Eugene Hendifar, Sant P. Chawla, Doris Quon, Victoria S Chua, Lita Fernandez, Sandeep Nagre, Marita Okunnu, Bartosz Chmielowski, Arun S. Singh, Slava Akmaev, David Chatman, John McCook, Shen Luan, Rangaprasad Sarangarajan, Paul Y. Song, Niven R Narain
Journal: Journal of Clinical Oncology (2012)

3015 Background: BPM 31510 is a novel small molecule that targets the metabolic machinery of the cancer microenvironment to reverse the aerobic glycolytic phenotype of cancer cells. Effector downstream signaling results in re-capitulation of BCL-2 mediated apoptosis and disruption in tumor vasculature by modulation of VEGF. (NR Narain et al., Proceedings of AACR Meeting Abstracts 2011). Methods: A standard 3+3 phase I, dose-escalation study design was used in patients with advanced solid tumors refractory to standard treatment. Primary objectives were establishment of the maximum tolerated dose (MTD) and safety/pharmacokinetic (PK) correlates. Secondary objectives included exploratory pharmacodynamics (PD) and preliminary efficacy (RECIST-1.1) of BPM 31510 in sequential cohorts of 3 to 6 pts. Results: At time of submission, 34 patients with advanced cancer who had failed multiple chemotherapeutic regimens had been enrolled in 7 dose cohorts (ranging from 5.6 mg/kg to 78.2 mg/kg). Patients received a median of 2 cycles (1-7). 2 patients have had grade 3 elevation in PT/INR, otherwise there have been no grade 3/4 treatment related toxicities to date. The pharmacokinetics of BPM 31510 are linear and there were no sex differences in the parameters normalized by dose and body surface area. T max and C max are associated with the end of the infusion. The values for t 1/2 ranged from 2.18 to 13.3 hr, with little or no dependence of t 1/2 on dose. Objective tumor responses have been noted at the dose of 58.6mg/kg with 1 partial response (myxoid liposarcoma) and 1 minor response (pleomorphic sarcoma). Six patients (19%) have had disease stabilization (&gt; 4 months). Conclusions: Interim data from this phase I study indicate that BPM 31510 is well tolerated with no dose limiting toxicities to date. A partial response and minor response were observed and correlates with dose escalation. Taken together, there is strong rationale for further clinical development of this compound as an anti-cancer agent.
Endoscopic transpapillary gallbladder drainage using the balloon occlusion method to advance the guidewire into the cystic duct
Authors: Kazunari Nakahara, Yosuke Michikawa, Ryo Morita, Keigo Suetani, Shinjiro Kobayashi, Takehito Otsubo, Fumio Itoh
Journal: Endoscopy (2020)

Endoscopic transpapillary gallbladder drainage (ETGBD) is effective for patients in whom cholecystectomy or percutaneous transhepatic gallbladder drainage (PTGBD) is contraindicated [1] [2]. However, in some patients, the guidewire cannot be advanced into the cystic duct because of the caudal distribution of the cystic duct. Herein, we present a case in which use of the balloon occlusion method enabled guidewire insertion into a cystic duct with caudal distribution, thus allowing ETGBD to be successfully performed.
QUANTITATIVE ASSESSMENT OF MYOCARDIAL HYPERMETABOLISM AND PERFUSION FOR DIAGNOSIS OF CARDIAC SARCOIDOSIS
Authors: Robert J. H Miller, Adele Pope, Evan Paul Kransdorf, Michele A. Hamilton, Jignesh Patel, Sean W. Hayes, John Friedman, Louise Thomson, Balaji Tamarappoo, Daniel S. Berman, Piotr Slomka
Journal: Journal of the American College of Cardiology (2020)
Determinants of Outcome in Patients With Left Ventricular Impairment and Moderate Aortic Stenosis
Authors: Carl Hayward, George Thornton, Alex Asher, Sara Tyebally, Anirban Ray-Chaudhuri, Cian Mangan, Kyriacos Mouyis, George Harvey, Saad Saheecha, Simiao Liu, Arvind Singhal, Nina Karia, Ketna Patel, Guy Lloyd, Sanjeev Bhattacharyya
Journal: JACC. Cardiovascular imaging (2020)
LEFT VENTRICULAR MASS TO VOLTAGE RATIO IS ASSOCIATED WITH HEART FAILURE HOSPITALIZATION IN CARDIAC AMYLOIDOSIS
Authors: Jeremy Slivnick, Alex Wallner, Ajay Vallakati, Vien T. Truong, Wojciech Mazur, Mohamed Elamin, Subha V. Raman, Karolina M. Zareba
Journal: Journal of the American College of Cardiology (2020)
GEOGRAPHICAL AND BASELINE CHARACTERISTICS AMONG MEDICARE BENEFICIARIES WHO EXPERIENCED CARDIOGENIC SHOCK, 2014-2017
Authors: Chau Truong, Randa Hamden, Trudy M. Krause, David Aguilar, Soumya Patnaik, Poyee Tung, Savitri E. Fedson, Vijay Nambi, Jaime Hernandez Montfort
Journal: Journal of the American College of Cardiology (2020)
BPI20-014: Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50
Authors: Robin M. Lally, Elizabeth Reed, Roksana Zak
Journal: Journal of the National Comprehensive Cancer Network (2020)

"BPI20-014: Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50" published on 20 Mar 2020 by National Comprehensive Cancer Network.
THE IMPACT OF MORPHOLOGY ON SINGLE VENTRICLE FUNCTION, ATRIOVENTRICULAR VALVE COMPETENCY AND CLINICAL OUTCOMES IN OVER 1,100 FONTAN PATIENTS: A 30 YEAR, SINGLE-CENTER STUDY
Authors: Jiyong Moon, Li Shen, Donald Likosky, Vikram Sood, Reilly D. Hobbs, Sassalos Peter, Jennifer C. Romano, Richard G. Ohye, Edward Bove, Ming-Sing Si
Journal: Journal of the American College of Cardiology (2020)
RELATIONSHIP BETWEEN PERICORONARY ADIPOSE TISSUE ATTENUATION ON COMPUTED TOMOGRAPHY ANGIOGRAPHY AND CORONARY PLAQUE CHARACTERISTICS ON OPTICAL COHERENCE TOMOGRAPHY
Authors: Tomoyo Sugiyama, Yoshihisa Kanaji, Masahiro Hoshino, Masao Yamaguchi, Masahiro Hada, Toru Misawa, Yohei Sumino, Hidenori Hirano, Kai Nogami, HIroki Ueno, Taishi Yonetsu, Tetsuo Sasano, Tsunekazu Kakuta
Journal: Journal of the American College of Cardiology (2020)